10-K: BioAdaptives Inc. Reports Full Year 2023 Results, Focuses on Growth and Subsidiary Independence

BioAdaptives, Inc. released its 2023 annual report, highlighting a shift towards wholesale distribution and the potential spin-off of its Livestock Impact subsidiary, while navigating financial challenges.

Summary

• BioAdaptives, Inc., a company focused on natural health products for humans and animals, filed its 10-K report for the year ended December 31, 2023.
• The company's core business involves investigating, marketing, and distributing plant, algal, and mushroom-based products and medical devices.
• Revenues for 2023 were $28,565, up from $17,176 in 2022, but operating expenses totaled $239,740.
• The company reported a net loss of $712,466 for 2023, compared to a net loss of $895,570 in 2022.
• BioAdaptives is exploring wholesale and white-label markets for its human supplements, as direct web sales have not generated significant revenue.
• The Livestock Impact subsidiary has seen a 400% increase in wholesale volume after appointing an exclusive distributor.
• The company is planning to launch new human products in the first half of 2024, including Pluripain PMS, VeganHepplus, and NaturaComplete.
• BioAdaptives is also exploring the botanical drugs sphere and has acquired non-exclusive licenses for several products.
• The company has 3 full-time and 3 part-time employees and relies on consultants for various business functions.
• BioAdaptives has a history of losses and relies on external financing, including convertible debt and Reg A+ offerings, to maintain operations.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are some positive developments, such as the growth of the Livestock Impact subsidiary and the launch of new products, the company's financial situation is precarious, with significant losses and reliance on external funding. The risks and challenges outlined in the report outweigh the positives, resulting in a low sentiment score.

Positives

• The company's revenue increased year-over-year.
• The Livestock Impact subsidiary has shown significant growth in sales volume.
• BioAdaptives is expanding its product line with new human supplements.
• The company is exploring new markets, including botanical drugs.
• The company is actively seeking alternative sales channels, including wholesale and white-label opportunities.
• The net loss decreased compared to the previous year.

Negatives

• The company has a history of losses and relies on external financing.
• Direct web sales of human nutraceuticals have not generated significant revenue.
• The company has limited experience in marketing and lacks reliable sales forecasting.
• Sales of the Lung Cleanser medical device have not met expectations.
• The company is not taking up the option to purchase a patent for oxygenating water due to technical issues.
• The company has a significant accumulated deficit of $8,264,145 as of December 31, 2023.

Risks

• The company has a limited operating history with its current business model.
• BioAdaptives is reliant on external financing and may not be able to secure additional funding.
• The company faces considerable risks in its business plan and a potential shortfall of funding.
• The company's marketing and exposure suffer from a lack of an advertising budget.
• The company is subject to competition in the nutraceutical industry.
• The company's internal controls may be inadequate, which could cause financial reporting to be unreliable.
• The market for BioAdaptives shares is extremely limited and sporadic.
• The company's common stock is a penny stock, which is restricted by SEC regulations.
• The company may not be able to attract and retain qualified personnel and consultants.
• The company's success depends on key individuals, and their loss could have an adverse effect.

Future Outlook

The company plans to market its existing products, continue research and development, and seek strategic acquisitions. BioAdaptives anticipates launching new human products in the first half of 2024 and is focused on expanding its marketing efforts, particularly for its Livestock Impact subsidiary. The company also intends to pursue international sales and explore new product opportunities.

Management Comments

• Management believes that its current finance partners, shareholders, and the proceeds from its potential Reg. A+ offering will be able to provide sufficient working capital.
• Management acknowledges that its Plan of Operations may not result in the consistent generation of positive working capital in the near future.
• Management believes that its expectations as to its ability to secure additional capital are reasonable but there is no guarantee that the Company will receive sufficient funding to sustain operations or implement any future business plan steps.

Industry Context

BioAdaptives operates in the competitive nutraceutical and medical device industry. The company's focus on natural, plant-based products aligns with growing consumer interest in wellness and alternative health solutions. The shift towards wholesale distribution reflects a common strategy for companies seeking to expand their market reach. The company's exploration of botanical drugs also aligns with a growing trend in the industry.

Comparison to Industry Standards

• BioAdaptives' revenue of $28,565 is significantly lower than established companies in the nutraceutical industry, which often report revenues in the millions or billions of dollars.
• The company's reliance on external financing and convertible debt is common among early-stage companies but poses a risk to long-term sustainability.
• The 400% increase in wholesale volume for Livestock Impact is a positive sign, but it is important to note that this is from a low base and the margins are tighter.
• The company's net loss of $712,466 is typical for a company in its early stages of development, but it highlights the need for improved revenue generation and cost management.
• Compared to companies like Herbalife or GNC, BioAdaptives is a very small player with limited resources and market presence.
• The company's focus on specific niches, such as equine and canine products, may provide a competitive advantage but also limits its overall market potential.

Related Party Transactions

• The company has related party transactions with BioScience Associates, Ltd., managed by Dr. Edward E. Jacobs, Jr.
• The company has granted licenses for its principal nutraceutical products from Essence Worldwide, Ltd., Essence Now, Ltd., and LiveStock Impact, Ltd.
• The company has related party notes payable.

Stakeholder Impact

• Shareholders face the risk of dilution due to the company's reliance on equity financing.
• Employees may be impacted by the company's financial instability.
• Customers may benefit from the company's new product launches.
• Suppliers may be affected by the company's financial challenges.
• Creditors face the risk of non-payment due to the company's financial difficulties.

Next Steps

• The company plans to market its existing products.
• BioAdaptives will continue conducting research and investigation activities to identify new products or markets.
• The company will seek strategic or complimentary acquisitions in its current market space.
• BioAdaptives intends to launch new human products in the first half of 2024.
• The company will intensify its marketing outreach in the next two quarters.
• The company is working at launching NaturaComplete All In One products in the first two quarters of 2024.
• The company will actively launch two new equine products in the first two quarters of 2024.

Key Dates

Keywords

nutraceuticals, dietary supplements, health and wellness, medical devices, Livestock Impact, wholesale distribution, botanical drugs, Reg A+, convertible debt, marketing, equine, canine